Skip to main content

Pipamperone









Pipamperone


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search


Not to be confused with Pirenperone.









































































Pipamperone
Pipamperone.svg
Clinical data
Synonyms McN-JR 3345; R-3345

AHFS/Drugs.com
 International Drug Names
Routes of
administration		 Oral
ATC code

  • N05AD05 (WHO)
Identifiers
CAS Number

  • 1893-33-0 ☒N

PubChem CID
  • 4830
IUPHAR/BPS
  • 92
ChemSpider

  • 4664 ☑Y
UNII
  • 5402501F0W
KEGG

  • D02622 ☑Y
ChEMBL

  • ChEMBL440294 ☑Y
ECHA InfoCard
100.119.828 Edit this at Wikidata
Chemical and physical data
Formula
C21H30FN3O2
Molar mass 375.480 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Pipamperone (INN, USAN, BAN), also known as carpiperone and floropipamide or fluoropipamide, and as floropipamide hydrochloride (JAN), is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia.[1][2] It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan.[2] Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.[3]




Contents






  • 1 Pharmacology


  • 2 Antidepressant effects


  • 3 See also


  • 4 References





Pharmacology[edit]




Pipamperon Neuraxpharm, 40mg



Pipamperone acts as an antagonist of the 5-HT2A,[4]5-HT2B,[5]5-HT2C[6]D2,[4]D3,[7]D4,[4][8]α1-adrenergic,[7] and α2-adrenergic receptors.[7] It shows much higher affinity for the 5-HT2A and D4 receptors over the D2 receptor (15-fold in the case of the D4 receptor, and even higher in the case of the 5-HT2A receptor),[4][7][9] being regarded as "highly selective" for the former two sites at low doses.[9][10] Pipamperone has low and likely insignificant affinity for the H1 and mACh receptors, as well as for other serotonin and dopamine receptors.[7]


Pipamperone is considered to have been a forerunner to the atypical antipsychotics, if not an atypical antipsychotic itself, due to its prominent serotonin antagonism.[11][12][13]



Antidepressant effects[edit]


Low-dose pipamperone (5 mg twice daily) has been found to accelerate and enhance the antidepressant effect of citalopram (40 mg once daily), in a combination (citalopram/pipamperone) referred to as PipCit (code name PNB-01).[9][14]



See also[edit]



  • Clozapine

  • Melperone

  • Pimozide

  • Risperidone



References[edit]





  1. ^ Dr. Ian Morton; I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 222–. ISBN 978-0-7514-0499-9..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ ab J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 985–. ISBN 978-1-4757-2085-3.


  3. ^ David Healy (1 July 2009). The Creation of Psychopharmacology. Harvard University Press. pp. 251–. ISBN 978-0-674-03845-5.


  4. ^ abcd Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996). "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding". Psychopharmacology. 124 (1–2): 57–73. doi:10.1007/bf02245606. PMID 8935801.


  5. ^ Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL (1996). "Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences". J. Pharmacol. Exp. Ther. 276 (2): 720–7. PMID 8632342.


  6. ^ Prinssen EP, Koek W, Kleven MS (2000). "The effects of antipsychotics with 5-HT(2C) receptor affinity in behavioral assays selective for 5-HT(2C) receptor antagonist properties of compounds". Eur. J. Pharmacol. 388 (1): 57–67. doi:10.1016/s0014-2999(99)00859-6. PMID 10657547.


  7. ^ abcde Bart A. Ellenbroek; Alexander R. Cools (6 December 2012). Atypical Antipsychotics. Birkhäuser. pp. 62–. ISBN 978-3-0348-8448-8.


  8. ^ Van Craenenbroeck K, Gellynck E, Lintermans B, Leysen JE, Van Tol HH, Haegeman G, Vanhoenacker P (2006). "Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor". Life Sci. 80 (1): 74–81. doi:10.1016/j.lfs.2006.08.024. PMID 16978659.


  9. ^ abc Wade AG, Crawford GM, Nemeroff CB, Schatzberg AF, Schlaepfer T, McConnachie A, Haazen L, Buntinx E (2011). "Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response". Psychol Med. 41 (10): 2089–97. doi:10.1017/S0033291711000158. PMID 21349239.


  10. ^ Michael S. Lidow (22 June 2000). Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press. pp. 88–. ISBN 978-1-4200-4177-4.


  11. ^ Awouters FH, Lewi PJ (2007). "Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen". Arzneimittelforschung. 57 (10): 625–32. doi:10.1055/s-0031-1296660. PMID 18074755.


  12. ^ Vanden Bussche G, Gelders YG, Heylen SL (1990). "[Development of new antipsychotic drugs]". Acta Psiquiatr Psicol Am Lat (in Spanish). 36 (1–2): 13–25. PMID 2127339.


  13. ^ Niemegeers CJ, Awouters F, Janssen PA (1990). "[Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone]". Encephale (in French). 16 (2): 147–51. PMID 1693560.


  14. ^ Kirk R (2010). "Clinical trials in CNS--SMi's eighth annual conference". IDrugs. 13 (2): 66–9. PMID 20127552.













Retrieved from "https://en.wikipedia.org/w/index.php?title=Pipamperone&oldid=800155780"





Navigation menu


























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.968","walltime":"1.164","ppvisitednodes":{"value":5627,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":464219,"limit":2097152},"templateargumentsize":{"value":118311,"limit":2097152},"expansiondepth":{"value":16,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":43880,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 750.436 1 -total"," 52.14% 391.246 1 Template:Drugbox"," 34.81% 261.247 1 Template:Infobox"," 25.01% 187.713 1 Template:Reflist"," 17.03% 127.815 22 Template:Navbox"," 11.32% 84.963 5 Template:Cite_book"," 10.64% 79.878 16 Template:Unbulleted_list"," 10.35% 77.670 1 Template:Navboxes"," 9.58% 71.917 9 Template:Cite_journal"," 7.07% 53.082 1 Template:Distinguish"]},"scribunto":{"limitreport-timeusage":{"value":"0.295","limit":"10.000"},"limitreport-memusage":{"value":6003709,"limit":52428800}},"cachereport":{"origin":"mw1318","timestamp":"20181231102643","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Pipamperone","url":"https://en.wikipedia.org/wiki/Pipamperone","sameAs":"http://www.wikidata.org/entity/Q415118","mainEntity":"http://www.wikidata.org/entity/Q415118","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2006-11-13T20:37:18Z","dateModified":"2017-09-11T20:24:38Z","image":"https://upload.wikimedia.org/wikipedia/commons/5/56/Pipamperone.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":102,"wgHostname":"mw1238"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more

13 indicted, 8 arrested in Calif. drug cartel investigation

Image
Fox News U.S. World Opinion Politics Entertainment Business Lifestyle TV Radio More Expand / Collapse search Login Watch TV ☰ Hot Topics U.S. Crime Military Education Terror Immigration Economy Personal Freedoms World U.N. Conflicts Terrorism Disasters Global Economy Environment Religion Scandals Opinion Politics Executive Senate House Judiciary Foreign policy Polls Elections Entertainment Celebrity News Movies TV News Music News Style News Entertainment Video Business Markets Politics Technology Features Business Leaders Lifestyle Food + Drink Cars + Trucks Travel + Outdoors House + Home Fitness + Well-being Style + Beauty Family Science Archaeology Air & Space Planet Earth Wild Nature Natural Science Dinosaurs Tech Security Innovation Drones Computers Video Games Military Tech Health Healthy Living Medical Research Mental Health Cancer Heart Health Children'
Read more